Drugs / Xagrotin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05017493 | Jul → Dec 2020 | COVID-19 | Biomad AS | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05222425 | Jun → Oct 2022 | COVID-19 | Biomad AS | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xagrotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222425 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “A herbal compound” NCT05222425 ↗ |